Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | https://doi.org/10.1186/s12876-022-02341-7 http://hdl.handle.net/1843/61841 http://orcid.org/0000-0002-7319-8906 http://orcid.org/0000-0002-8180-6254 http://orcid.org/0000-0002-8166-0304 http://orcid.org/0000-0002-4035-3113 http://orcid.org/0000-0003-1623-4525 http://orcid.org/0000-0002-5621-2657 http://orcid.org/0000-0002-2122-5538 http://orcid.org/0000-0002-7890-0848 http://orcid.org/0000-0002-4440-2023 http://orcid.org/0000-0002-1181-7329 http://orcid.org/0000-0003-1903-844X http://orcid.org/0000-0002-3985-7402 http://orcid.org/0000-0002-1250-2628 http://orcid.org/0000-0002-2132-8780 http://orcid.org/0000-0003-0867-6593 http://orcid.org/0000-0001-7509-7730 http://orcid.org/0000-0003-0344-9631 http://orcid.org/0000-0003-0153-4349 http://orcid.org/0000-0002-1032-5349 http://orcid.org/0000-0002-9516-0378 http://orcid.org/0000-0002-0412-2182 http://orcid.org/0000-0002-0916-4138 http://orcid.org/0000-0003-3046-2399 http://orcid.org/0000-0001-6684-8061 http://orcid.org/0000-0003-3256-4698 http://orcid.org/0000-0002-8915-7279 http://orcid.org/0000-0002-5533-5401 http://orcid.org/0000-0003-4563-2784 http://orcid.org/0000-0002-5443-7553 http://orcid.org/0000-0003-2857-0825 http://orcid.org/0000-0002-2053-5315 |
Resumo: | Background Anti-TNF therapy represented a landmark in medical treatment of ulcerative colitis (UC). There is lack of data on the efficacy and safety of these agents in Brazilian patients. The present study aimed to analyze rates of clinical and endoscopic remission comparatively, between adalimumab (ADA) and infliximab (IFX), in Brazilian patients with UC, and evaluate factors associated with clinical and endoscopic remission after 1 year of treatment. Methods A national retrospective multicenter study (24 centers) was performed including patients with UC treated with anti-TNF therapy. Outcomes as clinical response and remission, endoscopic remission and secondary loss of response were measured in different time points of the follow-up. Baseline predictive factors of clinical and endoscopic remission at week 52 were evaluated using logistic regression model. Indirect comparisons among groups (ADA and IFX) were performed using Student's t, Pearson χ2 or Fisher's exact test when appropriated, and Kaplan Meier analysis. Results Overall, 393 patients were included (ADA, n = 111; IFX, n = 282). The mean age was 41.86 ± 13.60 years, 61.58% were female, most patients had extensive colitis (62.40%) and 19.39% had previous exposure to a biological agent. Overall, clinical remission rate was 66.78%, 71.62% and 82.82% at weeks 8, 26 and 52, respectively. Remission rates were higher in the IFX group at weeks 26 (75.12% vs. 62.65%, p < 0.0001) and 52 (65.24% vs. 51.35%, p < 0.0001) when compared to ADA. According to Kaplan–Meier survival curve loss of response was less frequent in the Infliximab compared to Adalimumab group (p = 0.001). Overall, endoscopic remission was observed in 50% of patients at week 26 and in 65.98% at week 52, with no difference between the groups (p = 0.114). Colectomy was performed in 23 patients (5.99%). Age, non-prior exposure to biological therapy, use of IFX and endoscopic remission at week 26 were associated with clinical remission after 52 weeks. Variables associated with endoscopic remission were non-prior exposure to biological therapy, and clinical and endoscopic remission at week 26. Conclusions IFX was associated with higher rates of clinical remission after 1 year in comparison to ADA. Non-prior exposure to biological therapy and early response to anti-TNF treatment were associated with higher rates of clinical and endoscopic remission. |
id |
UFMG_336b4dc33e9d0a9026f18dfa2d6ef378 |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/61841 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
2023-12-07T21:25:38Z2023-12-07T21:25:38Z2022-05-2922268112https://doi.org/10.1186/s12876-022-02341-71471-230Xhttp://hdl.handle.net/1843/61841http://orcid.org/0000-0002-7319-8906http://orcid.org/0000-0002-8180-6254http://orcid.org/0000-0002-8166-0304http://orcid.org/0000-0002-4035-3113http://orcid.org/0000-0003-1623-4525http://orcid.org/0000-0002-5621-2657http://orcid.org/0000-0002-2122-5538http://orcid.org/0000-0002-7890-0848http://orcid.org/0000-0002-4440-2023http://orcid.org/0000-0002-1181-7329http://orcid.org/0000-0003-1903-844Xhttp://orcid.org/0000-0002-3985-7402http://orcid.org/0000-0002-1250-2628http://orcid.org/0000-0002-2132-8780http://orcid.org/0000-0003-0867-6593http://orcid.org/0000-0001-7509-7730http://orcid.org/0000-0003-0344-9631http://orcid.org/0000-0003-0153-4349http://orcid.org/0000-0002-1032-5349http://orcid.org/0000-0002-9516-0378http://orcid.org/0000-0002-0412-2182http://orcid.org/0000-0002-0916-4138http://orcid.org/0000-0003-3046-2399http://orcid.org/0000-0001-6684-8061http://orcid.org/0000-0003-3256-4698http://orcid.org/0000-0002-8915-7279http://orcid.org/0000-0002-5533-5401http://orcid.org/0000-0003-4563-2784http://orcid.org/0000-0002-5443-7553http://orcid.org/0000-0003-2857-0825http://orcid.org/0000-0002-2053-5315Background Anti-TNF therapy represented a landmark in medical treatment of ulcerative colitis (UC). There is lack of data on the efficacy and safety of these agents in Brazilian patients. The present study aimed to analyze rates of clinical and endoscopic remission comparatively, between adalimumab (ADA) and infliximab (IFX), in Brazilian patients with UC, and evaluate factors associated with clinical and endoscopic remission after 1 year of treatment. Methods A national retrospective multicenter study (24 centers) was performed including patients with UC treated with anti-TNF therapy. Outcomes as clinical response and remission, endoscopic remission and secondary loss of response were measured in different time points of the follow-up. Baseline predictive factors of clinical and endoscopic remission at week 52 were evaluated using logistic regression model. Indirect comparisons among groups (ADA and IFX) were performed using Student's t, Pearson χ2 or Fisher's exact test when appropriated, and Kaplan Meier analysis. Results Overall, 393 patients were included (ADA, n = 111; IFX, n = 282). The mean age was 41.86 ± 13.60 years, 61.58% were female, most patients had extensive colitis (62.40%) and 19.39% had previous exposure to a biological agent. Overall, clinical remission rate was 66.78%, 71.62% and 82.82% at weeks 8, 26 and 52, respectively. Remission rates were higher in the IFX group at weeks 26 (75.12% vs. 62.65%, p < 0.0001) and 52 (65.24% vs. 51.35%, p < 0.0001) when compared to ADA. According to Kaplan–Meier survival curve loss of response was less frequent in the Infliximab compared to Adalimumab group (p = 0.001). Overall, endoscopic remission was observed in 50% of patients at week 26 and in 65.98% at week 52, with no difference between the groups (p = 0.114). Colectomy was performed in 23 patients (5.99%). Age, non-prior exposure to biological therapy, use of IFX and endoscopic remission at week 26 were associated with clinical remission after 52 weeks. Variables associated with endoscopic remission were non-prior exposure to biological therapy, and clinical and endoscopic remission at week 26. Conclusions IFX was associated with higher rates of clinical remission after 1 year in comparison to ADA. Non-prior exposure to biological therapy and early response to anti-TNF treatment were associated with higher rates of clinical and endoscopic remission.engUniversidade Federal de Minas GeraisUFMGBrasilMED - DEPARTAMENTO DE CLÍNICA MÉDICAMEDICINA - FACULDADE DE MEDICINABMC GastroenterologyColite UlcerativaAdalimumabBrasilAnti-TNF therapyAdalimumabInfiximabClinical remissionUlcerative colitisAnti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02341-7Ligia Yukie SassakiMarley Ribeiro FeitosaCarlos Henrique Marques Dos SantosManoel Alvaro de Freitas Lins NetoAbel Botelho QuaresmaSergio Figueiredo de Lima JuniorGraciana Bandeira Salgado de VasconcelosOrnella Sari CassolArlene Dos Santos PintoGustavo KurachiFrancisco de Assis Goncalves FilhoDaniela Oliveira MagroRodrigo Galhardi GaspariniThaísa Kowalski FurlanWilson Roberto CatapaniCláudio Saddy Rodrigues CoyVivian de Souza MenegassiMarilia Majeski ColomboRenata de sá Brito FróesFabio Vieira TeixeiraAntonio Carlos MoraesGenoile Oliveira SantanaRogerio Saad-hossneJosé Miguel Luz ParenteEduardo Garcia VilelaNatália Sousa Freitas QueirozPaulo Gustavo KotzeJulio Pinheiro BaimaCristina FloresLucianna Motta CorreiaLívia Medeiros Soares CelaniMaria de Lourdes de Abreu FerrariPatricia Zachariasapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/61841/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALAnti-TNF therapy for ulcerative colitis in Brazil_ a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).pdfAnti-TNF therapy for ulcerative colitis in Brazil_ a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).pdfapplication/pdf336062https://repositorio.ufmg.br/bitstream/1843/61841/2/Anti-TNF%20therapy%20for%20ulcerative%20colitis%20in%20Brazil_%20a%20comparative%20real-world%20national%20retrospective%20multicentric%20study%20from%20the%20Brazilian%20study%20group%20of%20IBD%20%28GEDIIB%29.pdf5b3cf21c451166b82401be1a1baf4a46MD521843/618412023-12-07 18:25:39.209oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-12-07T21:25:39Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.pt_BR.fl_str_mv |
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB) |
title |
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB) |
spellingShingle |
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB) Ligia Yukie Sassaki Anti-TNF therapy Adalimumab Infiximab Clinical remission Ulcerative colitis Colite Ulcerativa Adalimumab Brasil |
title_short |
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB) |
title_full |
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB) |
title_fullStr |
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB) |
title_full_unstemmed |
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB) |
title_sort |
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB) |
author |
Ligia Yukie Sassaki |
author_facet |
Ligia Yukie Sassaki Marley Ribeiro Feitosa Carlos Henrique Marques Dos Santos Manoel Alvaro de Freitas Lins Neto Abel Botelho Quaresma Sergio Figueiredo de Lima Junior Graciana Bandeira Salgado de Vasconcelos Ornella Sari Cassol Arlene Dos Santos Pinto Gustavo Kurachi Francisco de Assis Goncalves Filho Daniela Oliveira Magro Rodrigo Galhardi Gasparini Thaísa Kowalski Furlan Wilson Roberto Catapani Cláudio Saddy Rodrigues Coy Vivian de Souza Menegassi Marilia Majeski Colombo Renata de sá Brito Fróes Fabio Vieira Teixeira Antonio Carlos Moraes Genoile Oliveira Santana Rogerio Saad-hossne José Miguel Luz Parente Eduardo Garcia Vilela Natália Sousa Freitas Queiroz Paulo Gustavo Kotze Julio Pinheiro Baima Cristina Flores Lucianna Motta Correia Lívia Medeiros Soares Celani Maria de Lourdes de Abreu Ferrari Patricia Zacharias |
author_role |
author |
author2 |
Marley Ribeiro Feitosa Carlos Henrique Marques Dos Santos Manoel Alvaro de Freitas Lins Neto Abel Botelho Quaresma Sergio Figueiredo de Lima Junior Graciana Bandeira Salgado de Vasconcelos Ornella Sari Cassol Arlene Dos Santos Pinto Gustavo Kurachi Francisco de Assis Goncalves Filho Daniela Oliveira Magro Rodrigo Galhardi Gasparini Thaísa Kowalski Furlan Wilson Roberto Catapani Cláudio Saddy Rodrigues Coy Vivian de Souza Menegassi Marilia Majeski Colombo Renata de sá Brito Fróes Fabio Vieira Teixeira Antonio Carlos Moraes Genoile Oliveira Santana Rogerio Saad-hossne José Miguel Luz Parente Eduardo Garcia Vilela Natália Sousa Freitas Queiroz Paulo Gustavo Kotze Julio Pinheiro Baima Cristina Flores Lucianna Motta Correia Lívia Medeiros Soares Celani Maria de Lourdes de Abreu Ferrari Patricia Zacharias |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Ligia Yukie Sassaki Marley Ribeiro Feitosa Carlos Henrique Marques Dos Santos Manoel Alvaro de Freitas Lins Neto Abel Botelho Quaresma Sergio Figueiredo de Lima Junior Graciana Bandeira Salgado de Vasconcelos Ornella Sari Cassol Arlene Dos Santos Pinto Gustavo Kurachi Francisco de Assis Goncalves Filho Daniela Oliveira Magro Rodrigo Galhardi Gasparini Thaísa Kowalski Furlan Wilson Roberto Catapani Cláudio Saddy Rodrigues Coy Vivian de Souza Menegassi Marilia Majeski Colombo Renata de sá Brito Fróes Fabio Vieira Teixeira Antonio Carlos Moraes Genoile Oliveira Santana Rogerio Saad-hossne José Miguel Luz Parente Eduardo Garcia Vilela Natália Sousa Freitas Queiroz Paulo Gustavo Kotze Julio Pinheiro Baima Cristina Flores Lucianna Motta Correia Lívia Medeiros Soares Celani Maria de Lourdes de Abreu Ferrari Patricia Zacharias |
dc.subject.por.fl_str_mv |
Anti-TNF therapy Adalimumab Infiximab Clinical remission Ulcerative colitis |
topic |
Anti-TNF therapy Adalimumab Infiximab Clinical remission Ulcerative colitis Colite Ulcerativa Adalimumab Brasil |
dc.subject.other.pt_BR.fl_str_mv |
Colite Ulcerativa Adalimumab Brasil |
description |
Background Anti-TNF therapy represented a landmark in medical treatment of ulcerative colitis (UC). There is lack of data on the efficacy and safety of these agents in Brazilian patients. The present study aimed to analyze rates of clinical and endoscopic remission comparatively, between adalimumab (ADA) and infliximab (IFX), in Brazilian patients with UC, and evaluate factors associated with clinical and endoscopic remission after 1 year of treatment. Methods A national retrospective multicenter study (24 centers) was performed including patients with UC treated with anti-TNF therapy. Outcomes as clinical response and remission, endoscopic remission and secondary loss of response were measured in different time points of the follow-up. Baseline predictive factors of clinical and endoscopic remission at week 52 were evaluated using logistic regression model. Indirect comparisons among groups (ADA and IFX) were performed using Student's t, Pearson χ2 or Fisher's exact test when appropriated, and Kaplan Meier analysis. Results Overall, 393 patients were included (ADA, n = 111; IFX, n = 282). The mean age was 41.86 ± 13.60 years, 61.58% were female, most patients had extensive colitis (62.40%) and 19.39% had previous exposure to a biological agent. Overall, clinical remission rate was 66.78%, 71.62% and 82.82% at weeks 8, 26 and 52, respectively. Remission rates were higher in the IFX group at weeks 26 (75.12% vs. 62.65%, p < 0.0001) and 52 (65.24% vs. 51.35%, p < 0.0001) when compared to ADA. According to Kaplan–Meier survival curve loss of response was less frequent in the Infliximab compared to Adalimumab group (p = 0.001). Overall, endoscopic remission was observed in 50% of patients at week 26 and in 65.98% at week 52, with no difference between the groups (p = 0.114). Colectomy was performed in 23 patients (5.99%). Age, non-prior exposure to biological therapy, use of IFX and endoscopic remission at week 26 were associated with clinical remission after 52 weeks. Variables associated with endoscopic remission were non-prior exposure to biological therapy, and clinical and endoscopic remission at week 26. Conclusions IFX was associated with higher rates of clinical remission after 1 year in comparison to ADA. Non-prior exposure to biological therapy and early response to anti-TNF treatment were associated with higher rates of clinical and endoscopic remission. |
publishDate |
2022 |
dc.date.issued.fl_str_mv |
2022-05-29 |
dc.date.accessioned.fl_str_mv |
2023-12-07T21:25:38Z |
dc.date.available.fl_str_mv |
2023-12-07T21:25:38Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/61841 |
dc.identifier.doi.pt_BR.fl_str_mv |
https://doi.org/10.1186/s12876-022-02341-7 |
dc.identifier.issn.pt_BR.fl_str_mv |
1471-230X |
dc.identifier.orcid.pt_BR.fl_str_mv |
http://orcid.org/0000-0002-7319-8906 http://orcid.org/0000-0002-8180-6254 http://orcid.org/0000-0002-8166-0304 http://orcid.org/0000-0002-4035-3113 http://orcid.org/0000-0003-1623-4525 http://orcid.org/0000-0002-5621-2657 http://orcid.org/0000-0002-2122-5538 http://orcid.org/0000-0002-7890-0848 http://orcid.org/0000-0002-4440-2023 http://orcid.org/0000-0002-1181-7329 http://orcid.org/0000-0003-1903-844X http://orcid.org/0000-0002-3985-7402 http://orcid.org/0000-0002-1250-2628 http://orcid.org/0000-0002-2132-8780 http://orcid.org/0000-0003-0867-6593 http://orcid.org/0000-0001-7509-7730 http://orcid.org/0000-0003-0344-9631 http://orcid.org/0000-0003-0153-4349 http://orcid.org/0000-0002-1032-5349 http://orcid.org/0000-0002-9516-0378 http://orcid.org/0000-0002-0412-2182 http://orcid.org/0000-0002-0916-4138 http://orcid.org/0000-0003-3046-2399 http://orcid.org/0000-0001-6684-8061 http://orcid.org/0000-0003-3256-4698 http://orcid.org/0000-0002-8915-7279 http://orcid.org/0000-0002-5533-5401 http://orcid.org/0000-0003-4563-2784 http://orcid.org/0000-0002-5443-7553 http://orcid.org/0000-0003-2857-0825 http://orcid.org/0000-0002-2053-5315 |
url |
https://doi.org/10.1186/s12876-022-02341-7 http://hdl.handle.net/1843/61841 http://orcid.org/0000-0002-7319-8906 http://orcid.org/0000-0002-8180-6254 http://orcid.org/0000-0002-8166-0304 http://orcid.org/0000-0002-4035-3113 http://orcid.org/0000-0003-1623-4525 http://orcid.org/0000-0002-5621-2657 http://orcid.org/0000-0002-2122-5538 http://orcid.org/0000-0002-7890-0848 http://orcid.org/0000-0002-4440-2023 http://orcid.org/0000-0002-1181-7329 http://orcid.org/0000-0003-1903-844X http://orcid.org/0000-0002-3985-7402 http://orcid.org/0000-0002-1250-2628 http://orcid.org/0000-0002-2132-8780 http://orcid.org/0000-0003-0867-6593 http://orcid.org/0000-0001-7509-7730 http://orcid.org/0000-0003-0344-9631 http://orcid.org/0000-0003-0153-4349 http://orcid.org/0000-0002-1032-5349 http://orcid.org/0000-0002-9516-0378 http://orcid.org/0000-0002-0412-2182 http://orcid.org/0000-0002-0916-4138 http://orcid.org/0000-0003-3046-2399 http://orcid.org/0000-0001-6684-8061 http://orcid.org/0000-0003-3256-4698 http://orcid.org/0000-0002-8915-7279 http://orcid.org/0000-0002-5533-5401 http://orcid.org/0000-0003-4563-2784 http://orcid.org/0000-0002-5443-7553 http://orcid.org/0000-0003-2857-0825 http://orcid.org/0000-0002-2053-5315 |
identifier_str_mv |
1471-230X |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
BMC Gastroenterology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.publisher.initials.fl_str_mv |
UFMG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
MED - DEPARTAMENTO DE CLÍNICA MÉDICA MEDICINA - FACULDADE DE MEDICINA |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/61841/1/License.txt https://repositorio.ufmg.br/bitstream/1843/61841/2/Anti-TNF%20therapy%20for%20ulcerative%20colitis%20in%20Brazil_%20a%20comparative%20real-world%20national%20retrospective%20multicentric%20study%20from%20the%20Brazilian%20study%20group%20of%20IBD%20%28GEDIIB%29.pdf |
bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 5b3cf21c451166b82401be1a1baf4a46 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
|
_version_ |
1803589428767096832 |